Aura Biosciences

Aura Biosciences is a biotechnology company focused on developing innovative cancer treatments. It is currently enrolling patients in the global Phase 3 CoMpass trial to evaluate the safety and efficacy of belzupacap sarotalocan (bel-sar) for treating small choroidal melanoma. The company utilizes a novel Virus-Like Drug Conjugates (VDCs) platform to target various solid tumors, with an emphasis on ocular and urologic oncology. Aura Biosciences aims to create a new standard of care in cancer treatment by offering early intervention options that preserve patient vision and improve long-term outcomes. The company is actively involved in research and clinical trials to address cancers like choroidal melanoma and non-muscle-invasive bladder cancer.